WO1999026535A1 - Reagent for tumor therapy and/or imaging - Google Patents
Reagent for tumor therapy and/or imaging Download PDFInfo
- Publication number
- WO1999026535A1 WO1999026535A1 PCT/US1998/024663 US9824663W WO9926535A1 WO 1999026535 A1 WO1999026535 A1 WO 1999026535A1 US 9824663 W US9824663 W US 9824663W WO 9926535 A1 WO9926535 A1 WO 9926535A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbohydrate
- reagent
- cell
- atom
- paramagnetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
- A61B5/416—Evaluating particular organs or parts of the immune or lymphatic systems the spleen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
Definitions
- This invention relates generally to materials for imaging or treating tumors and to methods for their use. More specifically, this invention relates to carbohydrate based materials which have a paramagnetic atom bonded thereto, and which are selectively taken up by tumors. Background of the Tnvention
- Magnetic resonance imaging has become an important non- invasive, medical technique over the past decade.
- the technique provides a mapped distribution of target nuclei.
- MRI uses a strong direct current magnetic field, in conjunction with tunable gradient magnetic fields to spatially control the locations at which the net sum magnetic field reaches a preselected value.
- a series of radio frequency (RF) pulses are applied.
- RF energy is at a resonance frequency of sample atoms, of a particular species and surroundings, those sample atomic nuclei absorb the RF energy and are excited to a higher spin state.
- the excited spin state then decays to a lower energy state of excitation, this decay often is accompanied emission of an RF pulse, this pulse is often referred to as a "spin echo.”
- the resonance frequency of a nucleus and its resulting spin echo signal depend on a number of factors including mass, density, dipole moment, relaxation frequency, as well as the chemical bonding and electrostatic potential of its surroundings. Instrument parameters such as pulse sequence, frequency, etc. also dictate the MRI imaging signal. Due to their abundance and favorable relaxation properties protons in either aqueous or lipid environments are preferred nuclei for MRI imaging.
- contrast agents include paramagnetic metal ions such as magenese, gadolinium and iron.
- paramagnetic metal ions such as magenese, gadolinium and iron.
- the free metal ions are generally quite toxic. In order to lessen toxicity, the metal ions have in the past typically been chelated with small organic molecules or polymers. However, chelation tends to decrease the interactive effects of the metal ions, especially at the higher RFs.
- chelated metal ions do not possess satisfactory cell membrane transport properties, nor biodistribution to tissues of particular interest, such as tumors.
- the contrast reagents of the instant invention allow for MRI imaging and monitoring of tumors that are smaller than is currently possible by computed axial tomography (CAT). Thus, tumors are detected earlier and without the introduction of radioactive tracers, thus enhancing the possibility of successful treatment.
- CAT computed axial tomography
- Magnetic fields have also been shown to be a means to treat malignant tissues by inducing hyperthermia.
- the selective excitement of metal ions using RF radiation offers the prospect of killing cells selectively incorporating a metal ion with only minor or reversible damage to surrounding cells.
- Previous efforts have been hampered by difficulties in targeting the metal ion to specific cells and generating localized hyperthermia.
- the reagent comprises a carbohydrate, which is capable of binding to, or penetrating, a cancerous cell.
- the carbohydrate has a paramagnetic atom bonded thereto, and further includes a carrier suitable for delivery of the carbohydrate to the cancerous cell.
- the paramagnetic atom comprises gadolinium.
- the carrier may comprise liposomes, which encapsulate the carbohydrate.
- the carbohydrate is D-glucose, and the gadolinium atom is bonded to the 2' position thereof.
- the carbohydrate may be a glucose isomer, and the gadolinium atom may be bonded to either the 2' or 3' position.
- the reagent comprises gadolinium glucoside.
- a method for treating a tumor cell which comprises delivering to the cell a carbohydrate capable of binding to, or penetrating, the cell.
- the carbohydrate has a paramagnetic atom bonded thereto.
- the carbohydrate material is allowed to bind or penetrate the cell, and the cell is then exposed to a magnetic field having a sufficient flux and frequency to cause resonance in the paramagnetic atom so that a Curie temperature of greater than about 60°C is generated within the tumor cell.
- the paramagnetic atom may comprise iron, gadolinium or manganese.
- a reagent for the treatment of a tumor cell comprises a carbohydrate selected from the group consisting of monosaccharides, disaccharides and polysaccharides.
- the carbohydrate has an iron atom bonded thereto.
- the present invention overcomes many of the disadvantages associated with existing contrast reagents and hyperthermic agents, including reduced toxicity and increased selectivity of tumor uptake.
- the present invention manipulates the ability of cells, and especially tumor cells to accumulate carbohydrates from the bloodstream.
- the use of carbohydrates and in particular monosaccharides as ligands to stabilize paramagnetic metal ions is the basis of the tumor therapy and imaging methodologies detailed herein.
- Carbohydrates are important metabolites in cell function. As cell metabolism increases, the cellular uptake of carbohydrates similarly increases. Thus, a growing tumor mass accumulates a greater per cell percentage of available carbohydrates than will surrounding, non-replicating tissue.
- Suitable paramagnetic metal ions operative in the instant invention include, but are not limited to, carbohydrates containing transition metals, lanthanide and actinide elements, and any of the suitable paramagnetic ions thereof. Illustrative of the ions of such elements are: Cu(II),
- the ions are Fe(III), Gd(III), and Mn(II).
- Metallated-carbohydrates that are operative in the instant invention are limited only by the requirement that they be capable of binding or penetrating a tumor cell.
- suitable biocompatible compounds that are operative in the instant invention illustratively include: pentose monosaccharides, such as ribose, arabinose, xylose, lyxose; hexoses, such as alose, altrose, glucose, gulose, mannose, idose, galactose, fructose, and talose; disaccharides such as sucrose, maltose, cellubiose and lactose; polysaccharides such as cellulose and agarose; the pyranoses thereof; the furanoses thereof; the glycosides thereof; the sugar alcohols thereof; and the deoxy sugars thereof.
- the D enantiomers of carbohydrates are utilized, for reasons including cellular recognition and biocompatibility.
- the carbohydrate is D-glucose.
- a dative or covalent bond between the metal ion and the carbohydrate allows for the delivery of the metal ion to either a cell surface or interior.
- the metal ion is alternatively bound to the carbohydrate through an alcoholic oxygen linkage, a hemiacetal, or a linkage to the carbon backbone of the carbohydrate.
- the metal ion is secured to the carbohydrate via an oxygen linkage. It is appreciated that additional small ligands may be bound to the metal ion, in order to satisfy the ion valency.
- the metal ion is directed to various bonding sites on the carbohydrate through the use of conventional carbohydrate chemistry techniques and purifications.
- the use of protecting groups such as acetals and ketals to effectively protect certain of the hydroxyl groups during reactions of carbohydrates is well known in the art.
- reagents such as acetone and diethoxypropane under suitable reaction conditions the metallization of carbohydrates is directed to specific sites. Owing to the importance of the C-l and C-4 binding sites in polymerization and cellular recognition, it is preferred that the carbohydrates of the instant invention be metallated at the C-2 or C-3 positions.
- positions other than C-2 and C-3 are operative positions for attachment of paramagnetic metal ions when such sites offer desired membrane transport, toxicity, or therapeutic properties.
- the metal ion is most preferably bonded at the C-2 position, owing to stearic considerations.
- the metallated carbohydrates of the instant invention are delivered to a patient in doses preferably ranging from one to five mg/kg.
- the metallated carbohydrates of the invention may be administered, in a suitable pharmaceutical carrier by a variety of routes, including: nasally, orally, intramuscularly, subcutaneously and intravenously.
- an adjuvant illustratively including mineral gels such as aluminum hydroxide, surface active substances such as lecithin, naturally occurring carbohydrates, peptides, oil emulsions and the like.
- the reagents of the instant invention may further include conventional formulation aids, for example stabilizers, antioxidants, osmolality adjustment agents, buffers, pH adjusting agents and the like.
- a solution in a sterile physiologically acceptable medium for example, an isotonic or somewhat hypertonic aqueous solution is preferred.
- the reagents of the instant invention operate by affecting the relaxation time of water protons. The time interval associated with the rate of proton energy transfer to the surrounding chemical environment, Tl, is decreased by the presence of the reagents of the instant invention, thereby increasing the local image intensity of cells wherein the reagent has concentrated.
- D-glucose binding gadolinium at the C-2 position is used in MRI imaging with a conventional RF pulse sequence resonate with consistent species associated with gadolinium in an aqueous environment.
- a further aspect of the invention involves a method of selectively killing tumor cells through localized magnetically coupled, RF induced hyperthermia. Using the predetermined coordinates of tumorous cells which have incorporated a reagent of the instant invention, the area is exposed to a magnetic field of sufficiently low frequency that dielectric heating effects are negligible, so as to protect normal surrounding tissue.
- the same low frequency magnetic field induces significant magnetization, coercive forces and hysteresis losses in those cells in contact with or containing the reagent of the instant invention, thereby resulting in localized hysteresis heating.
- Such low frequency magnetic fields are obtained from an induction coil and a generator containing apparatus.
- the magnetic fields are controlled in terms of amplitude and tissue penetration depth to further minimize spurious hyperthermia.
- the apparatus by raising the temperature of localized areas to the range of 41-44°C preferentially destroys malignant cells, while normal tissue remains viable up to a temperature of about 48 °C.
- D-glucose metallated at the C-2 position by an iron atom is utilized within the instant invention as a reagent for hyperthermia treatment of tumor cells.
- Combinations of paramagnetic ion metallated-carbohydrates are within the scope of the present invention.
- simultaneous administration of carbohydrates containing different metal ions increases in the relaxivity and contrast enhancement are obtainable.
- delivery of D-glucose- Fe with D-glucose-Gd takes into account the superior contrast properties of gadolinium; relative to iron, and the superior hyperthermia properties of iron relative to gadolinium.
- the simultaneous administration of reagents allows for iterative MRI imaging and hyperthermal treatments.
- the reagents of the instant invention are also amenable to encapsulation within an enteric coating, a vesicle, or a liposome.
- Encapsulation serves to protect the metallated carbohydrates of the instant invention from digestive tract metabolism or to selectively enhance uptake into particular organs, such as the reticuloendothial organs: of liver, spleen and bone marrow.
- organs such as the reticuloendothial organs: of liver, spleen and bone marrow.
- gadolinium containing carbohydrate is encapsulated within a vesicle or liposome for imaging of tissues; and an iron containing carbohydrate is used for hyperthermal treatment thereof.
- vesicles or liposomes may further contain conventional chemotherapeutic agents such as Cis-Platin for the treatment of solid tumors and inflammatory lesions. Owing to the high metabolic rate of cancerous cells, these cells preferentially endocytosize vesicles or liposomes.
- chemotherapeutic agents such as Cis-Platin for the treatment of solid tumors and inflammatory lesions. Owing to the high metabolic rate of cancerous cells, these cells preferentially endocytosize vesicles or liposomes.
- the increased temperature associated with hysteresis heating of a cell containing conventional chemotherapeutic agents through the simultaneous administration with the reagents of the instant invention increases the chemical activity of the conventional chemotherapeutics through the increase in cellular temperature resulting from exposing the cells to suitable low frequency magnetic fields. In this way the reagents of the instant invention enhance the efficacy of known chemotherapeutics without directly killing the cell by means of hyperthermia.
- One material having particular utility comprises gadolinium glucoside.
- This material has the general structure shown in Figure 1 , and comprises three glucose molecules bonded to gadolinium through the oxygens thereof via coordinate bonds.
- the material of Figure 1 can be synthesized by a procedure wherein 6.9 grams (0.300 mole) of sodium are completely dissolved in a mixture of 200 ml of anhydrous isopropanol and 100 ml of tetrahydrofuran, in a first step.
- anhydrous (water content less than 100 ppm) gadolinium trichloride (25.0 g, 0.0948 mole) is added in portions to the sodium solution.
- the resulting mixture is stirred at reflux for five hours, and then allowed to stand at room temperature for 24 hours so as to produce a colorless solution of gadolinium triisopropoxide and a sodium chloride precipitate.
- About 100 ml of the isopropoxide solution is evacuated in a Schlenk vessel, and the residue is dissolved in 150 ml of deoxygenated, anhydrous dimethylformamide.
- a 10 ml aliquot of the resulting solution is analyzed for Gd content utilizing EDTA titration in the presence of urotropin buffer, with xylenol orange as a metallochromic indicator.
- 90 ml of the DMF solution having a concentration of 0.232 M/l (20.88 mole) is mixed in an inert atmosphere with 11.9 g (66.05 mole) anhydrous alpha-D-glucose in 92 ml of anhydrous DMF.
- the reaction mixture is heated for 30 minutes at 90-95 °C and poured into 1.2 1 of dry chloroform.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU14643/99A AU1464399A (en) | 1997-11-20 | 1998-11-19 | Reagent for tumor therapy and/or imaging |
JP2000521746A JP2001523693A (en) | 1997-11-20 | 1998-11-19 | Tumor treatment and / or imaging agent |
EP98958644A EP1032304A1 (en) | 1997-11-20 | 1998-11-19 | Reagent for tumor therapy and/or imaging |
CA002310841A CA2310841A1 (en) | 1997-11-20 | 1998-11-19 | Reagent for tumor therapy and/or imaging |
IL13621098A IL136210A (en) | 1997-11-20 | 1998-11-19 | Paramagnetic carbohydrate reagent for tumor imaging and/or treatment |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6708197P | 1997-11-20 | 1997-11-20 | |
US19534198A | 1998-11-18 | 1998-11-18 | |
US09/195,341 | 1998-11-18 | ||
US60/067,081 | 1998-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999026535A1 true WO1999026535A1 (en) | 1999-06-03 |
Family
ID=26747464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/024663 WO1999026535A1 (en) | 1997-11-20 | 1998-11-19 | Reagent for tumor therapy and/or imaging |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1032304A1 (en) |
JP (1) | JP2001523693A (en) |
CN (1) | CN1299249A (en) |
AU (1) | AU1464399A (en) |
CA (1) | CA2310841A1 (en) |
IL (1) | IL136210A (en) |
WO (1) | WO1999026535A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1852107A1 (en) * | 2006-04-19 | 2007-11-07 | Nanobiotix | Magnetic nanoparticles compositions and uses thereof |
CN102242081B (en) * | 2010-03-17 | 2013-01-02 | 中国人民解放军南京军区南京总医院 | Super paramagnetic iron oxide particle marked cell for magnetic-resonance tracing in vivo |
CN102078624B (en) * | 2010-12-23 | 2012-07-25 | 华东理工大学 | Efficient Gd-loaded liposome preparation and preparation method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4822594A (en) * | 1987-01-27 | 1989-04-18 | Gibby Wendell A | Contrast enhancing agents for magnetic resonance images |
US4986980A (en) * | 1984-11-01 | 1991-01-22 | Nycomed As | Water-soluble, carrier-bound paramagnetic metal containing diagnostic agents |
US5143716A (en) * | 1991-02-01 | 1992-09-01 | Unger Evan C | Phosphorylated sugar alcohols, Mono- and Di-Saccharides as contrast agents for use in magnetic resonance imaging of the gastrointestinal region |
US5268165A (en) * | 1990-10-16 | 1993-12-07 | Biomedical Frontiers, Inc. | Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging |
US5368840A (en) * | 1990-04-10 | 1994-11-29 | Imarx Pharmaceutical Corp. | Natural polymers as contrast media for magnetic resonance imaging |
US5707604A (en) * | 1986-11-18 | 1998-01-13 | Access Pharmaceuticals, Inc. | Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles |
-
1998
- 1998-11-19 AU AU14643/99A patent/AU1464399A/en not_active Abandoned
- 1998-11-19 EP EP98958644A patent/EP1032304A1/en not_active Withdrawn
- 1998-11-19 CN CN98812156A patent/CN1299249A/en active Pending
- 1998-11-19 IL IL13621098A patent/IL136210A/en not_active IP Right Cessation
- 1998-11-19 JP JP2000521746A patent/JP2001523693A/en active Pending
- 1998-11-19 CA CA002310841A patent/CA2310841A1/en not_active Abandoned
- 1998-11-19 WO PCT/US1998/024663 patent/WO1999026535A1/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4986980A (en) * | 1984-11-01 | 1991-01-22 | Nycomed As | Water-soluble, carrier-bound paramagnetic metal containing diagnostic agents |
US5707604A (en) * | 1986-11-18 | 1998-01-13 | Access Pharmaceuticals, Inc. | Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles |
US4822594A (en) * | 1987-01-27 | 1989-04-18 | Gibby Wendell A | Contrast enhancing agents for magnetic resonance images |
US5368840A (en) * | 1990-04-10 | 1994-11-29 | Imarx Pharmaceutical Corp. | Natural polymers as contrast media for magnetic resonance imaging |
US5268165A (en) * | 1990-10-16 | 1993-12-07 | Biomedical Frontiers, Inc. | Polymer-deferoxamine-ferric iron adducts for use in magnetic resonance imaging |
US5143716A (en) * | 1991-02-01 | 1992-09-01 | Unger Evan C | Phosphorylated sugar alcohols, Mono- and Di-Saccharides as contrast agents for use in magnetic resonance imaging of the gastrointestinal region |
Also Published As
Publication number | Publication date |
---|---|
CN1299249A (en) | 2001-06-13 |
IL136210A0 (en) | 2001-05-20 |
AU1464399A (en) | 1999-06-15 |
IL136210A (en) | 2005-11-20 |
EP1032304A1 (en) | 2000-09-06 |
CA2310841A1 (en) | 1999-06-03 |
JP2001523693A (en) | 2001-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1339821C (en) | Magnetic resonance imaging agents | |
US5077037A (en) | Novel compositions for magnetic resonance imaging | |
Zhang et al. | A gadolinium (III) zeolite-like metal-organic-framework-based magnetic resonance thermometer | |
EP3283493B1 (en) | Texaphyrin-phospholipid conjugates and methods of preparing same | |
US20060204443A1 (en) | Methods for tumor treatment using dendrimer conjugates | |
JPH06506468A (en) | Melanin image enhancer | |
US5458870A (en) | Compositions for magnetic resonance imaging using a manganese oxalate | |
Furmanski et al. | Metalloporphyrin enhancement of magnetic resonance imaging of human tumor xenografts in nude mice | |
EP0361960A2 (en) | Methods and compositions for magnetic resonance imaging | |
EP3037107B1 (en) | Polymer nanoparticle composite and composition for mri imaging including same | |
EP0470188B1 (en) | Novel magnetic resonance imaging agents | |
WO1999026535A1 (en) | Reagent for tumor therapy and/or imaging | |
US20220288206A1 (en) | Nanoparticles for the treatment of cancer by radiofrequency radiation | |
AU656355B2 (en) | Alkoxyamide derivatized chelates for MRI | |
EP0948361B1 (en) | Magnetic resonance blood pool agents | |
Pushparaj et al. | Development of novel dinuclear [Gd (III) DO3VA] complexes decorated with isovaleric acid as MRI contrast agents for tumor diagnosis | |
US20040166062A1 (en) | Ablation therapy using chemical shift magnetic resonance imaging | |
Matsumura et al. | Mn-metalloporphyrin conjugated with Gd-DTPA (Gd-ATN10): tumor enhancement agent for magnetic resonance imaging | |
WO1994010182A1 (en) | High relaxivity, paramagnetic, metal complexes for magnetic resonance imaging | |
Rezaei Aghdam et al. | 18 F-FDG MicroPET and MRI Targeting Breast Cancer Mouse Model with Designed Synthesis Nanoparticles | |
EP0977598A1 (en) | Nmr image compounds | |
KR100448100B1 (en) | Paramagnetic metal-phthalocyanine complex compounds and contrast agent using the same | |
Aminolroayaei et al. | Chitosan–Imidazolium Core–Shell Nanoparticles of Gd-Mn-Mo Polyoxometalate as Novel Potential MRI Nano-Agent for Breast Cancer Detection. Micromachines 2023, 14, 741 | |
JP2006052222A (en) | Metal complex salt having bioactivity and paramagnetic property and containing triaminotetracarboxy saccharide compound as ligand | |
Tokunori | 5406947 Magnetic resonance imaging apparatus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 136210 Country of ref document: IL Ref document number: 98812156.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2310841 Country of ref document: CA Ref document number: 2310841 Country of ref document: CA Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2000 521746 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998958644 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998958644 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998958644 Country of ref document: EP |